DSA’s healthcare partnership is with 2 seasoned professionals who have an unblemished track record in Healthcare and Investment space.

Dr. Manikanda Arunachalam

Dr.Manikanda Arunachalam is a multi disciplinary professional with expertise in Venture capital and private equity with sectoral interest in Medical Devices, genomics, Digital Health and Healthcare IOT

Mani serves as a board of Director in The KEF company, a multi million dollar private investment firm in Dubai International Financial center (DIFC). At KEF company Mani oversees the Healthcare investment portfolio and is a key strategist in managing the healthcare investments.

Mani Served as an Operating Partner in Capricorn Healthcare and Special opportunities (CHSO) Fund. CHSO is a health care middle market growth equity fund in Palo Alto.

Earlier Mani served as a board of director in Motherhood India, a chain of boutique mother and delivery care hospital, where he was responsible for capital raising through private equity placement and corporate strategy and planning. TPG acquired significant stake of Motherhood in 2016.

Mani worked as a strategic management consultant and has advised Provider organizations, Biotech and Medical devices firms. Currently serves on the board of HD medical group and Strategic advisor to Guardant Health.

Earlier he worked for Johnson and Johnson Medical devices where he was responsible for technology and portfolio management.

Mani started his career as a Cardiologist at the Apollo hospitals group in Chennai where he was trained in intervention cardiology. He was one of the pioneers in conducting multinational clinical trials as an investigator for Eli Lilly, Servier and Covance.

Mani Holds a MD degree from Prestigious Madras Medical college where he graduated among the
top 5% of the class, Fellowship in Cardiology and an MBA ( Finance & Strategy)from the Wharton School of The University of Pennsylvania.

Dr. Rizvi
Dr. Naiyer Rizvi

Dr. Naiyer A. Rizvi, M.D. is a co-founder of Gritstone Oncology Inc. Dr. Rizvi is a medical oncologist with specific expertise in thoracic oncology and immunotherapy drug development. He serves as Price Chair of Clinical Translational Medicine at Columbia University Medical Center (CUMC). He serves as Director of Thoracic Oncology and Immunotherapeutics at CUMC. During his last six years at MSKCC, his translational research was focused on immune-checkpoint blockade drug development. His research studies were integral to the approval of immune-checkpoint blockade in lung cancer including approval of nivolumab in squamous lung cancer (Lancet Oncology 2015) and pembrolizumab in non-small cell lung cancer (NEJM, 2015). His first-author publication in Science (2015) presented data from a landmark trial – the first study to demonstrate a statistically significant correlation between mutations and neo-antigens with durable benefit to immune-checkpoint blockade. He was an attending physician in thoracic oncology and early drug development from 2002 to 2014 at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. Rizvi obtained his M.D. at University of Manitoba in Winnipeg, Canada and went on to complete a fellowship in medical oncology at Beth Israel Hospital/Harvard Medical School.